Solid Tumor Clinical Trials in San Antonio, Texas

19 studies are recruiting for solid tumor in San Antonio, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

   This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Center for Cancer Research, San Antonio, Texas

   Locations

   20 in total

   Run by

   Terremoto Biosciences Inc.

   See if you can join NCT07109726 on ClinicalTrials.gov

2. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

   BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The stu…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START San Antonio, San Antonio, Texas

   Locations

   49 in total

   Run by

   Institut de Recherches Internationales Servier

   See if you can join NCT05786924 on ClinicalTrials.gov

3. A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

   AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be re…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology, San Antonio, Texas

   Locations

   7 in total

   Run by

   Angiex, Inc.

   See if you can join NCT06440005 on ClinicalTrials.gov

4. A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors

   The goal of this clinical study is to learn more about the study drug GS-1206, including its safety, tolerability, and antitumor activity in adult participants with solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology, San Antonio, Texas

   Locations

   4 in total

   Run by

   Gilead Sciences

   See if you can join NCT07703878 on ClinicalTrials.gov

5. Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

   This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   South Texas Accelerated Research Therapeutics, San Antonio, Texas

   Locations

   25 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT05245500 on ClinicalTrials.gov

6. STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

   This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalimab (anti- programmed cell death 1 [PD-1]) in advanced unresectable or metastatic tumors. The Phase 2…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology, San Antonio, Texas

   Locations

   10 in total

   Run by

   STORM Therapeutics LTD

   See if you can join NCT06975293 on ClinicalTrials.gov

7. FOG-001 in Locally Advanced or Metastatic Solid Tumors

   The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas

   Locations

   33 in total

   Run by

   Parabilis Medicines, Inc.

   See if you can join NCT05919264 on ClinicalTrials.gov

8. A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors

   The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0253 in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutated advanced solid tumors as monothera…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   New Experimental Therapeutics of San Antonio LLC, San Antonio, Texas

   Locations

   15 in total

   Run by

   PAQ Therapeutics, Inc.

   See if you can join NCT06797336 on ClinicalTrials.gov

9. A Study of ASP3082 in Adults With Advanced Solid Tumors

   This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP3082. The study aims to check how safe and well-tolerated ASP3082 is for people with advanced solid tumors that have a specific mutation called KRAS G12D. This study will be in 2…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology, San Antonio, Texas

   Locations

   66 in total

   Run by

   Astellas Pharma Inc

   See if you can join NCT05382559 on ClinicalTrials.gov

10. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

    This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizuma…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology, San Antonio, Texas

    Locations

    42 in total

    Run by

    Inhibrx Biosciences, Inc

    See if you can join NCT04198766 on ClinicalTrials.gov

11. A Phase 1 Study of BHV-1530 in Advanced Solid Tumors

    This is a Phase 1, first in human (FIH), Open-Label, Dose Escalation, Dose Expansion and Dose Optimization Study of BHV-1530 as Monotherapy and in Combination with Other Anti-Cancer Agents in Adult Participants with Advanced or Metastatic Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Site-105, San Antonio, Texas

    Locations

    17 in total

    Run by

    Biohaven Therapeutics Ltd.

    See if you can join NCT06874335 on ClinicalTrials.gov

12. A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

    The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy and in combination with cetuximab in participants with colorectal can…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    New Experimental Therapeutics of San Antonio LLC, San Antonio, Texas

    Locations

    9 in total

    Run by

    PAQ Therapeutics, Inc.

    See if you can join NCT07300150 on ClinicalTrials.gov

13. A Study of PYX-201 in Advanced Solid Tumors

    The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT San Antonio, San Antonio, Texas

    Locations

    29 in total

    Run by

    Pyxis Oncology, Inc

    See if you can join NCT05720117 on ClinicalTrials.gov

14. A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

    This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE[s]); and the dose expansion stage is to evaluate the preliminary antitumor act…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Exelixis Clinical Site #2, San Antonio, Texas

    Locations

    11 in total

    Run by

    Exelixis

    See if you can join NCT06952010 on ClinicalTrials.gov

15. Study of STP938 (Dencatistat) in Advanced Solid Tumours

    The Phase 1a part of the study is a dose escalation of STP938 as a monotherapy. The Phase 1b part of the study is a safety expansion cohort of STP938 as a monotherapy.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Next Oncology, San Antonio, Texas

    Locations

    7 in total

    Run by

    Step Pharma, SAS

    See if you can join NCT06297525 on ClinicalTrials.gov

16. Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors

    This is a study that will enroll patients with cancer who have tumors that may have spread. The patients will know what medication they are being given. There will be 2 parts to the study. For the first part of the study only one medication will be taken, and the dose changed to a higher dose over …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Texas Health Science Center at San Antonio, San Antonio, Texas

    Run by

    Lei Zheng

    See if you can join NCT07086768 on ClinicalTrials.gov

17. A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

    This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START San Antonio, San Antonio, Texas

    Locations

    15 in total

    Run by

    OnCusp Therapeutics, Inc.

    See if you can join NCT06234423 on ClinicalTrials.gov

18. First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

    The purpose of this study is to determine the safety, blood concentrations and treatment effect of CRB-601 in combination with immunotherapy in patients who have advanced solid tumors (cancer) and have exhausted other therapeutic options.CRB-601 targets a protein called avb8 integrin which is expre…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START - San Antonio, San Antonio, Texas

    Locations

    26 in total

    Run by

    Corbus Pharmaceuticals Inc.

    See if you can join NCT06603844 on ClinicalTrials.gov

19. Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

    This study consists of phase 1b and 2a to evaluate safety, Pharmacokinetics, and efficacy of TU2218 in combination with Pembrolizumab in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology, San Antonio, Texas

    Locations

    11 in total

    Run by

    TiumBio Co., Ltd.

    See if you can join NCT05784688 on ClinicalTrials.gov